Nature to add open-access publishing option in 2021
Nature Medicine Impact Factor 2019, 2018, 2017, 2016, 2015, 2014, 2013 | Resurchify
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England - The Lancet
What's a Good Impact Factor & Why It Matters. An 4-Step Journey - SCI Journal
Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers.,Nature Medicine - X-MOL
PLOS ONE: The Impact of Economic Crises on Communicable Disease Transmission and Control: A Systematic Review of the Evidence
Wearable sensor data and self-reported symptoms for COVID-19 detection | Nature Medicine
uv gullas college of medicine admissions cebu city philippines by uvgullas.com - issuu
Top 20 Medical Journals for Physicians to Publish in - The Kolabtree Blog
Ayurveda, Nature's Medicine eBook by David Frawley - 9781608690527 | Rakuten Kobo United States
What's a Good Impact Factor & Why It Matters. An 4-Step Journey - SCI Journal
Uživatel Nature Medicine na Twitteru: „Toni Ribas @UCLA will next talk at #KSCancerImm about novel immune #checkpointblockade combos. He recently showed that treatment with anti-PD-1 or anti-PD-L1 agents produces a high response
What a massive database of retracted papers reveals about science publishing's 'death penalty' | Science | AAAS
Nature Medicine Publishes JNU Professor's Research - Jinan University
IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma. - Nat. Med. - X-MOL
Women's knowledge: traditional medicine and nature; Mauritius, Reunion and Rodrigues - UNESCO Digital Library
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes | Nature Medicine
How to Get Into NYU Medical School: Requirements and Strategies — Shemmassian Academic Consulting
Journal of Medical Case Reports | Home page
Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease | Request PDF
Nature Medicine در توییتر "First up from 2018: #Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk #melanoma results in higher response rates than nivolumab monotherapy #NMEDClinical | https://t.co/QpHRjqbFdk ...
How to Get Into Harvard Medical School: Requirements and Strategies — Shemmassian Academic Consulting
Nature (journal) - Wikipedia
